In 2010, around 130 brands like Zoloft and Lipitor constituted for 34% of the universal pharma sector sales. Following the same year, many other drug companies hewed from the permit. The sector has changed in countless ways.
According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
Diabetes Australia's (the third oldest diabetes association in the world) latest figures show that over 200,000 women have suffered gestational diabetes during the last 10 years and is expected to exceed 500,000 within the next decade. Gestational diabetes can be fatal if untreated and could likely lead to overweight babies, premature births, as well as PreEclampsia.
The team is focusing to make Alex, the voice assistant, more convenient and useful in the health-care sector, which requires regulations and data privacy set by the HIPAA – Health Insurance Portability and Accountability Act. The experts are aiming to work on diabetes management, assistance for mother, infants and the elderly.
A technology that can change the way women check their baby’s health is in the final stages of development. PulseNmore LTD, an Israeli startup is developing a handheld ultrasound device that can be connected to any smartphone for monitoring the growth of a fetus.
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder. The company plans to seek regulatory approval for its ketamine-based esketamine nasal spray this year and if given the green light it will be the first new approach for the indication in nearly 50 years.
It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.